15 communities simultaneously launched free osteoporosis clinics. HSN facilitates the “China’s osteoporosis experts’ opinions” them science popularization project

Osteoporosis is one of the serious social problems faced by the aging society. However, there are still many misunderstandings and gaps in the public’s understanding of it. On March 23, the “China’s osteoporosis experts’ opinions” science popularization project free clinic event was held simultaneously in 15 communities in 6 districts of Guangzhou, including Haizhu, Baiyun, Panyu, Huangpu, Yuexiu, and Liwan, benefiting nearly 10,000 residents. The event was hosted by Sun Yat-sen Memorial Hospital of Sun Yat-sen University. Nearly 50 medical staff and volunteers from the Department of Orthopedics and General Medicine of the hospital went deep into the community to screen the general public for osteoporosis using LINGLONG AI DXA Machines and provided them with professional bone health guidance.

It is understood that this community free clinic, osteoporosis and fracture risk survey will be used as important data sources to form “China’s osteoporosis experts’ opinions” to help promote early detection, early diagnosis and early treatment of osteoporosis patients, and to promote the improvement of bone health of all citizens.

Free clinical treatment held simultaneously in many communities and the research results will form “China’s osteoporosis experts’ opinions”

“I often have low back pain and leg pain. Do I have osteoporosis?” “I suspect that I have osteoporosis. What tests should I do?” “I have been diagnosed with osteoporosis. What should I pay attention to in my daily diet?” At the Mingcui Plaza, Guangzhou site for the “Keep bones healthy & stay young” theme “China’s osteoporosis experts’ opinions” science popularization project, medical staff patiently answered questions raised by the public. In addition to answering questions on site, the Department of Orthopedic Surgery and General Medicine of Sun Yat-sen Memorial Hospital of Sun Yat-sen University also worked with community doctors to popularize health knowledge about osteoporosis to residents who came for treatment and carried out osteoporosis risk tests for them.

According to statistics, the prevalence of osteoporosis ranks first among the five major diseases of middle-aged and elderly people. It seriously endangers the health of the elderly and has become one of the serious social issues of widespread concern in the world today. As China’s aging population deepens, osteoporosis, as an aging disease, has attracted more and more attention from all walks of life. At present, China has become one of the countries with a high incidence of osteoporosis in the world, with approximately 90 million patients, accounting for approximately 7% of the total population. Data provided by the Chinese member units of the International Osteoporosis Foundation show that the annual incidence rate of fractures due to osteoporosis in China exceeds 9%, which has a trend of increasing every year.

In response to the call of the “Healthy China 2030” Planning Outline and to practice the “three reductions and three health” healthy lifestyle, the Chinese Medical Association’s Healthy World magazine and the Beijing Hongyi Medical Development Foundation jointly launched the “China’s osteoporosis experts’ opinions “Science popularization project. The project convenes experts in the field of osteoporosis prevention, diagnosis and treatment, and based on the results of on-site community free clinic surveys and the Guidelines for the Diagnosis and Treatment of Primary Osteoporosis 2022 Edition, Consensus on the Clinical Application of Vitamin D and Its Analogues and China’s Bone Health Science Guide and other documents, compiled popular science articles on “Expert Opinions on Osteoporosis in China” and conducted publicity and promotion, helped to promote early detection, early diagnosis, and early treatment of osteoporosis patients, and facilitated the improvement of bone health for the entire population. Community free clinics, osteoporosis and fracture risk surveys are very important components of the project’s data sources. Guangzhou is the first stop, and free clinics activities will also be held in Beijing and Shanghai in the future.

In order to attract more residents to understand and participate in this free clinic activity, each community health service center uses the family doctor platform and the radiation network of community residents committees to deliver free clinic information to community residents in advance, which has provided residents with the opportunity to obtain relevant knowledge on osteoporosis prevention, treatment, and management through community free clinical treatment, and also laid a solid foundation for the implementation of the concept of “being the first person responsible for one’s own health.”

The current situation of prevention and control is not satisfying.

The prevention and treatment process of osteoporosis should cover the entire life cycle

Professor Ding Yue, the leading expert in the free clinical treatment in Guangzhou and the director of the Orthopedic Surgery Department of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, pointed out that as the aging of the population accelerates, osteoporosis has received increasing attention. Currently, about 90 million people have been diagnosed with osteoporosis in China. If people with reduced bone mass are included, the number of people has exceeded 200 million. However, the current status of osteoporosis prevention and control in China is not satisfying, and there are still many misunderstandings and gaps in the public’s understanding of the disease.

“Community is the basic unit of urban public services and urban governance. The three-level osteoporosis prevention and control network based on community health service centers will effectively promote the development of osteoporosis prevention and control. It is the unshirkable social responsibility of medical science and technology workers to disseminate authoritative, scientific and accurate medical science knowledge and improve public health literacy. “Professor Ding Yue said.

Strong bones are the key to maintaining human health, and the prevention and treatment of osteoporosis should be throughout life. The main prevention and treatment goals of osteoporosis include improving bone growth and development and promoting ideal peak bone mass in adulthood; maintaining bone mass and bone quality to prevent age-related bone loss; avoid falls and bone fractures. As a basic supplement for bone health, adequate vitamin D can increase intestinal calcium absorption, promote bone mineralization, maintain muscle strength, improve balance, and reduce the risk of falls.

Calcium and vitamin D supplementation are particularly important for bone health. A cross-sectional study of healthy people in five major cities in my country showed that up to 88.3% of the people surveyed were vitamin D deficient. Regarding ordinary vitamin D and active vitamin D (such as calcitriol and alfacalcidol), the public has relatively little knowledge about their use and efficacy.

The imported original drug Rocaltrol, as a classic osteoporosis drug, can effectively increase BMD, prevent falls, and reduce the risk of fractures. In order to make it easier for more patients to purchase osteoporosis drugs, we have set up a purchase channel on the official account “Almighty Bone Guardian”.

“Almighty Bone Guardian” is primarily based on the WeChat official account, with a project mini-program for convenient and quick online medication purchase, free re-diagnosis and prescription as main services, along with additional services such as pharmacy navigation, electronic medical records, and patient education column.

During the free clinical treatment, the hospital’s expert team and volunteers explained the osteoporosis knowledge in detail to the citizens who came for consultation, and used the LINGLONG AI DXA Machine to provide free BMD test for them. Many citizens expressed that through this event, they gained a deeper understanding of osteoporosis and paid more attention to their bone health.

Our goal is to let more people understand osteoporosis and pay attention to bone density testing, so as to prevent and detect early osteoporosis. We will continue to participate in similar free clinical treatment across the country and use our technology and services to contribute to public health.

Narcolepsy is a globally recognized rare disease. In Asia, the prevalence rate of this condition is 0.0129% in Taiwan and 0.015% in South Korea. The peak age of onset in China is 8-12 years old. Currently, narcolepsy faces challenges such as low public awareness, low diagnosis rate and insufficient effective treatment drugs.

“Tetralogy” is a common symptom of narcolepsy, which is very disturbing to life. (Tetralogy includes excessive daytime sleepiness, cataplexy attack, hypnagogic hallucination and sleep paralysis.)

On June 30, 2023, Pitolisant Hydrochloride Tablets were approved in China for the treatment of adult narcolepsy indications. On December 13, 2023, Pitolisant Hydrochloride Tablets in two formulations were successfully included in the 2023 National Medical Insurance Negotiation Drug List. Pitolisant Hydrochloride Tablets are the world’s first H3 receptor antagonist/inverse agonist that increases the synthesis and release of the wakefulness-promoting neurotransmitter histamine in the brain by enhancing histaminergic neuron activity, thereby improving wakefulness and alertness in patients.

From December 2023 to January 2024, the “Awakening Dreams, Creating the Future – Expert Consultation on Pitolisant Hydrochloride Tablets for Narcolepsy” was held in Guangzhou, Beijing and Shanghai. Renowned professors and experts from major hospitals in China participated, discussing guidelines interpretation, disease recognition, drug treatment and case sharing, and providing new perspectives on the treatment of narcolepsy, a globally recognized rare disease.

In Guangzhou, 17 guests from more than 10 hospitals such as Guangdong Provincial People’s Hospital, The First Affiliated Hospital of Jinan University, Nanfang Hospital of Southern Medical University, and the Affiliated Brain Hospital of Guangzhou Medical University, attended the meeting. Overall, the feedback from the professors and experts on Pitolisant Hydrochloride Tablets was positive, considering it a clinical necessity in the current absence of effective treatments for narcolepsy. Pitolisant Hydrochloride Tablets are considered first-line therapy for the tetralogy associated with narcolepsy.

In Beijing, 14 professors and experts from over 10 hospitals including Xuanwu Hospital Capital Medical University, Beijing Chaoyang Hospital, Beijing Tiantan Hospital, Capital Medical University, The First Hospital of Hebei Medical University, West China Hospital, Sichuan University, Tianjin Medical University General Hospital, Peking University Third Hospital, the Second People’s Hospital of Guizhou Province, Tianjin Children’s Hospital, attended the meeting. Professors and experts emphasized the strong advantages of the drug itself, while also highlighting concerns about its accessibility and pricing, as well as the comorbidity associated with narcolepsy. The professors and experts generally provided positive feedback. Different departments may bring about different prescription opportunities, and there is a need to accelerate coverage in pediatrics and children’s hospitals. However, attention needs to be given to the doctor-patient relationship in cross-indication treatments. Doctors also face issues about patient management and combing, and hope to conduct more patient education and other patient activities.

In Shanghai, 10 professors and experts from 10 hospitals including the Second Affiliated Hospital of Naval Medical University, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai Sixth People’s Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai Ninth People’s Hospital Affiliated to Shanghai JiaoTong University School of Medicine, and Shanghai Children’s Medical Center Affiliated to Shanghai JiaoTong University School of Medicine, attended the meeting. The professors and experts believed that it is very challenging for rare disease drugs to be included in national medical insurance negotiations and that this inclusion can benefit more patients. Sleep troubles teenagers and adults, and tit is an important direction of neurology in the future. Sleeping too much or too little is a disease. Pitolisant Hydrochloride Tablets, as they are gradually used in clinical practice, will deepen the understanding of the disease. The experts expressed their hope for more indications to be approved in China.

To enhance the diagnosis and treatment of narcolepsy, promote exchanges and cooperation among medical units of provincial sleep coordination groups, and strengthen the construction of professional team of sleep disorders in sleep centers, HSN organized two special academic salons on narcolepsy in January 2024, covering more than 200 sleep experts from Shaanxi, Heilongjiang, Jilin and Liaoning provinces.

The meeting of the provincial sleep collaboration group for the three northeastern provinces was held on January 26 via Tencent Meeting, with over 70 participants. Yang Yi, Vice President (Deputy Secretary) of the First Bethune Hospital of Jilin University, delivered the opening speech, and Professor Wang Zan chaired the meeting and lectured on Identification and Treatment of Narcolepsy, emphasizing the need of the disease for long-term medication, the disease’s threat to life safety, learning ability, economic burden and employment. He also pointed out low public awareness rate, long diagnosis time, and differential diagnosis of combined diseases. Through research, he shared the relieving effect of Pitolisant on tetralogy, and looked forward to the launch of Pitolisant. Professor Zhu Yulan from the 2nd Affiliated Hospital of Harbin Medical University explained the Interpretation of China’s Narcolepsy Guidelines 2022, emphasizing the first-tier recommendation status of Pitolisant. Professor Tang Mingyang from the First Bethune Hospital of Jilin University shared clinical use cases of Pitolisant. Other attending experts, including Professor Liu Yansong, Professor Wang Xinli, Professor Man Yuhong, Professor Kou Yuhong, Professor Lin Yongzhong, Professor Liu Xiaoyang, Professor Sun Qingqing, etc., all contributed insights into the diagnosis and treatment of narcolepsy. Professor Wang Zan summarized that the first meeting of 2024, specifically focusing on narcolepsy, was a conference of the Northeast-Inner Mongolia Sleep Disorder Diagnosis and Treatment Alliance. It provided a deeper understanding of the epidemiology, mechanisms, diagnosis and treatment of narcolepsy. This meeting marks a significant step forward in the direction of sleep disorders in the three northeastern provinces and Inner Mongolia in 2024.

The Shaanxi Narcolepsy Alliance Academic Salon was held on January 27 via Tencent Meeting, with over 140 participants. Professor Su Changjun from Tangdu Hospital of Air Force Medical University served as the chairman of the meeting. It was an honor to invite Professor Zhan Shuqin from Xuanwu Hospital Capital Medical University and Professor Zhou Junying from West China Hospital, Sichuan University as speakers. Professors Lin Hai from Xi’an Hospital of Traditional Chinese Medicine and Guo Hena from Shaanxi Provincial People’s Hospital hosted the meeting. Professors Wang Xiaoli and Lv Xiaojuan shared cases of hypersomnia, and conducted case discussions with guests including Professor Yang Rui, Professor Li Guibin and Professor Yu Qijin. The invited speakers at this meeting performed excellently in their choice of topics and relevance. Professor Zhan Shuqin’s explanation of narcolepsy, the mechanism of Pitolisant, and real case analysis, along with Professor Zhou Junying’s EDS consensus interpretation, highlighted the advantages and status of Pitolisant. Both experts explained CNS hypersomnia from the etiology, pathogenesis, clinical manifestations, auxiliary examination, diagnostic criteria, differential diagnosis and other aspects, especially focusing on recent advances in treatment. Professor Su Changjun, the chairman of the meeting, concluded that Pitolisant’s imminent arrival in Shaanxi Province will benefit more narcolepsy patients. This meeting provided the participants with valuable learning and communication opportunities, deepened their understanding of narcolepsy and its treatment through the speakers’ wonderful sharing and case discussion, and provided useful enlightenment for medical practice. He hopes to continue organizing similar academic salons in the future to promote academic exchange and cooperation.

Narcolepsy is a severe sleep disorder, mainly characterized by excessive daytime sleepiness, cataplexy attack, sleep paralysis, and nocturnal sleep disturbance. This disease not only affects the life quality of patients, but can also lead to accidents and career limitations. HSN, in collaboration with sleep collaboration groups of each province in China, is dedicated to the narcolepsy doctor education, and continually deepening the construction of sleep medicine sub-specialty.

Guangzhou TV Station Live Report: “LINGLONG” BMD Test: Prevention and Early Intervention are Key to Osteoporosis.

October 20 every year is the World Osteoporosis Day. This date is set to raise public awareness of osteoporosis, promote the awareness that osteoporosis is preventable and treatable, reduce the risk of fractures in the elderly, and save families and the state from the huge economic and social burden caused by fractures.

The China’s theme for World Osteoporosis Day 2023 was “Strong Muscles, Healthy Bones, Preventing and Treating Osteoporosis”. On this special day, HSN actively participated in hospitals’ free clinical treatment activities in multiple cities of China, including Beijing, Shanghai and Guangzhou, to screen for osteoporosis among the general public with LINGLONG AI DXA Machine.

Photo of the Scene of Shanghai Sixth People’s Hospital Affiliated to Shanghai JiaoTong University

Photo of the Scene of Nanfang Hospital Affiliated to Southern Medical University

Photo of the Scene of Beijing Electric Power Hospital

Osteoporosis is a common bone disease, especially prevalent among middle-aged and elderly people. This disease often occurs without obvious symptoms and is only discovered when a bone fracture occurs. Therefore, regular BMD test is an important means of prevention and early detection of osteoporosis. Bone density, as the name suggests, refers to the “density of bone” and is the gold standard for diagnosing osteoporosis and an important basis for doctors to predict the risk of fractures. Currently, the most commonly used methods for testing BMD are dual-energy X-ray absorptiometry (DXA) and ultrasound bone densitometer.

LINGLONG AI DXA Machine is one of the most advanced BMD test devices on the market. It uses dual-energy X-ray absorptiometry (DXA) technology to accurately and quickly measure BMD, enabling early screening and diagnosis of osteoporosis, and it is the gold standard for osteoporosis diagnosis. Additionally, it is equipped with AI technology, which can automatically analyze test results and provide more accurate diagnostic basis for doctors. After the age of 35-40, BMD gradually decreases with age, so women over 50, perimenopausal women, and men over 60 are recommended for regular BMD test.

During the free clinical treatment, the hospital’s expert team and volunteers explained the osteoporosis knowledge in detail to the citizens who came for consultation, and used the LINGLONG AI DXA Machine to provide free BMD test for them. Many citizens expressed that through this event, they gained a deeper understanding of osteoporosis and paid more attention to their bone health.

In addition to prevention, for patients who already have osteoporosis, active drug treatment is also necessary. The imported original drug Rocaltrol, as a classic osteoporosis drug, can effectively increase BMD, prevent falls, and reduce the risk of fractures. In order to make it easier for more patients to purchase osteoporosis drugs, we have set up a purchase channel on the official account “Almighty Bone Guardian”.

“Almighty Bone Guardian” is primarily based on the WeChat official account, with a project mini-program for convenient and quick online medication purchase, free re-diagnosis and prescription as main services, along with additional services such as pharmacy navigation, electronic medical records, and patient education column.

(QR code) Scan the QR code to follow

Our goal is to raise people’s awareness of osteoporosis and attention of BMD test, and thereby prevent and detect osteoporosis early. We will continue to carry out similar free clinical treatment activities nationwide, and contribute to the public’s health with our technology and services.

Go forward hand in hand to create brilliance
RareStone & HSN Strategic Cooperation Press Conference

October 20th, 2023

On October 18, 2023, RareStone Group (hereinafter referred to as RareStone) and Zhejiang Hesenna Medicine Co., Ltd. (hereinafter referred to as HSN) successfully held a strategic cooperation press conference in Guangzhou, and signed a national general agent contract for Wakix^®!

Mr.Xiang Yu, CEO of RareStone, Mr. Xun Zhimeng, vice president and head of Citrine Medicine, Mr. Zhang Shengjie, vice president and head of finance, and Mr. Cao Heng, director of business and supply chain; Ms. Li Shu, Chairman of HSN, Mr. Yan Amin, General Manager, Ms. Liang Jianhua, Deputy General Manager, Ms. Fu Lingxia, Marketing Director, and Mr. Chen Duowen, Project Director, attended the signing ceremony.

At the beginning of the conference, CEO of RareStone, Mr. Xiang Yu and Vice President, Mr. Xun Zhimeng, together with Chairman of HSN, Ms. Li Shu and General Manager, Mr. Yan Amin, injected energy into the project at carefully selected auspicious moments to witness together the glorious moment when RareStone and HSN start their strategic cooperation!

Mr. Xiang Yu, CEO of RareStone, and Ms. Li Shu, Chairman of HSN, signed a strategic cooperation agreement as representatives of both parties. This strategic cooperation announcement marks a new stage of cooperation between the two companies, and will also be an important starting point for HSN to move into the field of rare disease treatment!

After the signing ceremony, the leaders of both parties gave sincere speeches!

Mr. Xiang Yu, CEO of RareStone, expressed the HSN team’s market access, market insights into the field of narcolepsy and WAKIX^® products since they contacted HSN in the past three months, as well as the enthusiasm and combat effectiveness of the frontline colleagues for the business have left a deep impression on RareStone! RareStone is full of confidence in the strategic cooperation and wishes the cooperation between the two sides a complete success!

.

Ms. Li Shu, Chairman of HSN, delivered a speech. The two companies quickly reached consensus on cooperation, which should give the credit to the good products of RareStone Group and also to the trust of RareStone Group in HSN. Due to its originality and excellent efficacy, WAKIX^® has become the most outstanding drug for the treatment of narcolepsy! The cooperation between the two companies comes at the right time. All HSN employees have attached great importance to it from top to bottom, and with the help of the national sales network, they will give full play to the professional, efficient and pragmatic style of the marketing team to cooperate with RareStone, complement each other’s advantages and achieve win-win cooperation so as to effectively promote market planning and layout and become a trustworthy partner for each other!

The strategic cooperation between RareStone and HSN is a cooperation between powerful enterprises for common development. Both parties will jointly draw a development blueprint to achieve a new leap in strategic development!

Attachment 1: Narcolepsy

Chinese Guidelines for the Diagnosis and Treatment of Narcolepsy (2022 Edition) pointed out that the concept of narcolepsy was first proposed by the French doctor Gélineau in 1880. Clinically, it is characterized by excessive daytime sleepiness (EDS), cataplexy, and nocturnal sleep disturbance. Narcolepsy can occur in childhood, and the average delay from onset to diagnosis is 8 to 22 years. The course of the disease spans critical periods of education and personal development. The clinical symptoms severely affect patients’ learning, life and social functioning, leading to difficulties in receiving normal education, employment, reduced income, and missed opportunities for career advancement.

Attachment 2: Pitolisant (Wakix®)

Pitolisant is a selective H3 receptor antagonist/inverse agonist that increases the synthesis and release of the wakefulness-promoting neurotransmitter histamine in the brain by enhancing histaminergic neuron activity, thereby improving wakefulness and alertness in patients. Pitolisant was granted breakthrough therapy designation by the FDA in October 2018.

On June 30, 2023, the National Medical Products Administration (NMPA) of China officially approved Wakix® (Pitolisant Hydrochloride Tablets) for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.

Attachment 3: Expert Consensus on the Clinical Diagnosis and Treatment of Excessive Daytime Sleepiness

– National Medical Journal of China, Vol. 103, No. 15, 2023-4-18

Excessive daytime sleepiness (EDS) refers to the inability to stay awake and alert for a period of time during which one needs to stay awake, with uncontrollable sleep needs or even involuntarily falling asleep, which can be accompanied by attention and memory impairment.

Currently, the first-line drug for the treatment of EDS based on current evidence from evidence-based medicine is Pitolisant.

Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting

Rocaltrol^® City Tour·Beijing Station

On July 20, 2023, the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol^® City Tour” jointly organized by Pharmanovia & Hesenna was successfully held at the Inner Mongolia Hotel in Beijing. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guidelines” for clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures.

The meeting was co-chaired by Professor Li Mei from Peking Union Medical College Hospital, chairman-designate of the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association, and Professor Xue Qingyun, chief expert of the Department of Orthopedics from Beijing Hospital, chairman of the Bone and Joint Committee of the Chinese Health Care Medical Research Association. An experienced speaker introduced the updated content of the new guideline, sorted out the important role of Rocaltrol in the field of osteoporosis, and shared rare clinical cases close to actual combat. Hospitals at all levels in Beijing participated wholeheartedly , the venue was full of enthusiasm.

After the meeting started, Professor Li Mei first welcomed the experts who participated in this meeting, and spoke highly of the platform provided by Hesenna, pointing out that under the current situation, the degree of population aging is getting more and more serious. Hesenna anchors the vision of the field of osteoporosis It is unique, and has a variety of excellent products such as bone density tester, Bonviva, and Rocaltrol in terms of diagnosis and treatment. It is full of hope and expectation for future cooperation with Hesenna in academic construction and scientific research.

Then Professor Li Mei invited Professor Tang Hai from Capital Medical University to share the updated content of the new guideline. Professor Tang Hai introduced the updated points in the guideline in detail, from the pathogenesis, risk assessment, diagnosis and treatment of primary osteoporosis In other aspects, Gao Jujian has made an in-depth interpretation, and the content is rich and detailed.

Afterwards, Professor Zhang Huachou from Beijing Hospital sorted out the drug treatment of primary osteoporosis. Professor Zhang introduced various drugs for osteoporosis treatment in detail, and gave a high evaluation of Rocaltrol’s clinical use. , pointing out that Rocaltrol is the basis of osteoporosis treatment, and taking the patients received as examples, emphasizing the important role of Rocaltrol in the field of osteoporosis, especially full of confidence in the efficacy of Rocaltrol in increasing muscle strength and preventing falls .

Immediately afterwards, Professor Zhang Jia from Peking Union Medical College Hospital explained in detail the clinical application and pharmacological mechanism of Rocaltrol. Professor Zhang Jia specifically mentioned that Rocaltrol can take effect directly without liver and kidney activation, which is very convenient and safe. In the field of primary osteoporosis treatment, Professor Zhang pointed out that calcium supplements combined with Rocaltrol can effectively reduce the risk of fractures, increase the muscle strength of osteoporosis patients, reduce the risk of falls, and bring many benefits to patients. In the treatment of osteoporosis, ordinary vitamin D cannot prevent bone loss, but Rocaltrol has a good effect in preventing bone loss.

Being based on the front line of clinical practice is also a highlight of this meeting. Dr. Xu Xiaojie from Beijing Jishuitan Hospital shared the cases based on actual combat, and the experts conducted further discussions on the cases. After the case sharing, the participating experts had a discussion on ordinary vitamin D and active vitamin D. Professor Li Mei pointed out that ordinary vitamin D is more used as a daily health supplement, and more active vitamin D may be better in treatment. The treatment options fully affirmed Rocaltrol’s position in the treatment of osteoporosis.

Finally, Professor Xue Qingyun made a summary of this meeting. Professor Xue pointed out that this meeting not only has theoretical knowledge, but also has case sharing close to clinical practice. Emphasize that Rocaltrol is an indispensable therapeutic drug in the treatment of osteoporosis. It is widely used in multi-departments and multi-disease fields, and it has been on the market in China for 30 years. It is an excellent drug. At the same time, I would like to thank Hesenna for its platform construction in the post-epidemic era.

The meeting was successfully carried out, realizing the purpose of building a doctor communication platform and promoting doctor linkage between departments and hospitals. It fully reflects Hesenna’s determination to focus on the field of osteoporosis and build an integration of osteoporosis diagnosis and treatment.